PRKN and cardiac hypertrophy: These findings align with emerging evidence that targeting mitochondrial quality control—particularly via PINK1/Parkin, FUNDC1, and SIRT1 pathways—can mitigate cardiac hypertrophy and dysfunction [11,12,13].